LUAA 399599

Drug Profile

LUAA 399599

Alternative Names: LU AA39959

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Class Antipsychotics
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bipolar depression; Bipolar disorders; Schizophrenia

Most Recent Events

  • 17 Mar 2010 Discontinued - Phase-II for Bipolar disorders in Denmark (PO)
  • 17 Mar 2010 Discontinued - Phase-II for Schizophrenia in Denmark (PO)
  • 04 Mar 2010 Preclinical development is ongoing and Lundbeck will make a decision on future development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top